AUSTIN, TX: Are you looking to speak with other investors about your favorite stock? Stockwire.com, ranked in the top 5,000 websites in the United States by Alexa.com/Amazon.com, has created one of the finest chat programs available for investors. Now you can chat real-time with like-minded individuals about your favorite stock. Visit Stockwire.com and click the "Chat Live" button at the top.
Chat real-time with other investors about this PPTI news release, by clicking this link: http://www.stockwire.com/PPTI
To view in-depth research, click the following link: http://www.stockwire.com/detailed/analysis.php?company=PPTI
Protein Polymer Technologies, Inc. (OTCBB: PPTI)
Protein Polymer Technologies, Inc., a biotechnology device company that is a pioneer in protein design and synthesis, announced today that they have entered into an agreement with a multinational pharmaceutical and medical device company. According to the agreement, PPTI will provide genetically engineered protein polymer biomaterials for use as surgical sealants. "Our sealant products have consistently performed well in evaluations by our corporate partners. We are excited about their demonstrated potential and look forward to further product development," said William N. Plamondon, CEO of Protein Polymer Technologies, Inc.
Wound closure after surgery or trauma using conventional sutures and staples sometimes results in post-operative complications such as persistent internal bleeding, fluid leaks after gastrointestinal surgery, or air leaks after lung surgery. In 2005, it was estimated that 70 million surgical procedures worldwide would benefit from the use of surgical sealants, glues and other wound closure products used in conjunction with sutures and staples. PPTI believes its protein polymer sealants and adhesives can improve the outcome of surgical wound closure by substantially reducing fluid and air leaks, especially as applied to endoscopic procedures in which access to the traumatized tissue is limited.
PPTI is also in discussions with several U.S. and international biotechnology and medical device companies, which are evaluating PPTI's adhesion barrier and drug delivery product applications. These products are intended to improve surgical outcomes by reducing adhesion formation and delivering to the surgical site beneficial pharmacological agents.
Chat real-time with other investors about this CGXP news release, by clicking this link: http://www.stockwire.com/CGXP
To view in-depth research, click the following link: http://www.stockwire.com/detailed/analysis.php?company=CGXP
Ceragenix Pharmaceuticals, Inc. (OTCBB: CGXP)
Ceragenix Pharmaceuticals, Inc., a biopharmaceutical company focused on infectious disease and dermatology, announced today that researchers at the University of Pennsylvania led by Dr. Paul Janmey and Dr. Robert Bucki, in collaboration with Dr. Paul B. Savage of Brigham Young University, have demonstrated in a series of in vitro experiments that an investigational drug compound known as CSA-13 shows promise as a potential therapy to treat multidrug resistant Pseudomonas aeuroginosa infections which are a leading cause of morbidity and mortality in patients with cystic fibrosis. The research appears ahead of print in an advanced online publication of the Journal of Antimicrobial Chemotherapy, the official journal of the British Society for Antimicrobial Chemotherapy.
In the reported research, Dr. Bucki and his colleagues evaluated the activity of a CSA-13, a member of the family of Ceragenin(TM) compounds being developed by Ceragenix. CSA-13 is a synthetic non-peptide mimic of the naturally occurring antimicrobial peptide found in the lung. The researchers found that CSA-13: -- Is significantly more effective than positively charged antibacterial peptides (LL-37) against a multidrug resistant strain of Pseudomonas aeuroginosa; -- Is far less susceptible to inactivation by negatively charged components found in the sputa of cystic fibrosis patients (DNA and F-actin); and that -- Is potent even in cystic fibrosis sputum thereby suggesting potential for therapeutic use.
"This new compound has the potential to be a significant advance in the treatment of patients with cystic fibrosis and other lung infections," says senior author Robert Bucki, a Senior Investigator at the University of Pennsylvania's Institute for Medicine and Engineering.
Normal healthy lungs are protected against bacterial infection by the presence of naturally occurring antimicrobial peptides such as LL-37 found in the lung fluid which form part of the body's innate immune system. These positively charged antimicrobial peptides are electrostatic attracted to the negatively charged membranes of bacteria. Once attached to the invaders' membranes, the antimicrobial peptides permeabilize and destroy the bacterial membranes leading to bacterial cell death. This highly effective mechanism of protecting the lung from bacterial infection does not work well in patients with cystic fibrosis as those patients have much higher levels of other negatively charged components in their sputum which bind to and inactivate the antimicrobial peptides. As a result, patients with cystic fibrosis are at high risk for lung infections throughout their lifetimes and the repeated bouts of lung infections scar the lung tissue and ultimately rob the patients of their ability to breathe.
"The conventional therapy used to treat Pseudomonas infections in cystic fibrosis patients is Tobramycin but there are an increasing number of Tobramycin resistant strains of Pseudomonas. There is an urgent need for the development of new antibiotics to treat these and other gram-negative bacterial infections," said Steven Porter, Chairman and CEO of Ceragenix Pharmaceuticals. "Our goal is to find a partner to help us advance development of this application."
Chat real-time with other investors about this ENEI news release, by clicking this link: http://www.stockwire.com/ENEI
To view in-depth research, click the following link: http://www.stockwire.com/detailed/analysis.php?company=ENEI
Ener1, Inc. (OTCBB: ENEI)
Ener1, Inc., an alternative energy company, announced on 6/29/07 that its controlling shareholder, Ener1 Group, has agreed to invest up to $15 million in Ener1 through the purchase of newly issued shares of common stock. The funds will be used for the continuing commercial development of lithium ion batteries for hybrid electric vehicles ("HEV's") and the product launch of its fuel-cell-powered surveillance camera. The investments will be funded based on operating requirements through December 31, 2007.
Ener1 Group agreed to purchase the shares at a price of $0.30 per share, which is 42% above the June 27, 2007 closing price of $0.21 per share. Ener1 will issue to Ener1 Group five-year warrants to purchase Ener1 common stock equal to 60% of the number of shares purchased during the investment period at an exercise price of $.30 per share. The warrant coverage could increase to 100% under certain circumstances. All warrants previously issued to Ener1 Group will be amended to change their exercise price to $0.30 per share from an average exercise price of $0.50 per share. The commitment amount will be reduced by any additional capital that Ener1 raises during the investment period.
Ener1 Group's obligation to provide this funding is conditioned upon Ener1's achievement of specific milestones related to its lithium ion battery and fuel-cell development efforts. The milestones for the next 180 days include production of a minimum number of lithium ion HEV battery packs, the award of a customer-funded Li-ion battery development contract, the award of a Phase II contract from the United States Advanced Battery Consortium (USABC), demonstration of EnerDel Li-Ion battery technology in a vehicle, and achievement of a minimum level of sales of the portable fuel-cell powered surveillance camera product currently in development. The agreement is subject to final documentation. Approximately $3.8 million of the $15.0 million has already been invested during June by Ener1 Group.
Charles Gassenheimer, Vice Chairman of Ener1, commented, "This tremendous commitment from Ener1 Group will allow Ener1 to gain ground in the development of the lithium ion battery for HEVs. It will also provide the funding to launch the surveillance camera product, which we expect to be very successful. This large financing commitment will allow us to focus on improving shareholder value through development of our business. In addition, we are working with our investment bankers to raise capital to fund our operations through the end of 2008 and also provide sufficient capital to restructure our long term debt. This financing structure gives us the financial flexibility to complete this additional financing when the market conditions are most beneficial to our shareholders." Subhash Dhar, President of Ener1, added, "Our success in the coming months will be measured by the delivery of production design prototypes and products in the battery and fuel cell businesses. These milestones are targets that we firmly believe we can achieve within the time period. Furthermore, this funding will be a clear signal to our prospective customers and industry partners that we have the financial strength to deliver products in these large emerging markets. We truly appreciate the continuing support and conviction of our controlling shareholder in making this substantial commitment to our future."
Chat real-time with other investors about this FVRG news release, by clicking this link: http://www.stockwire.com/FVRG
To view in-depth research, click the following link: http://www.stockwire.com/detailed/analysis.php?company=FVRG
ForeverGreen Worldwide Corporation (OTCBB: FVRG)
ForeverGreen Worldwide Corporation, a manufacturer and distributor of all natural whole foods, announced on 6/29/07 it has finalized product registration for sale of their lead product, FrequenSea, in Mexico, and is prepared to officially enter the Mexican market this summer.
Stemming from its entrance into the Latin-American market, ForeverGreen has taken the next step in its global expansion by registering FrequenSea for sale in Mexico. "Productos Naturales ForeverGreen Internacional en Mexico SA de CV" is now official and ForeverGreen is generating relationships with network distribution leaders in preparation of its official launch.
The Mexican Direct Sales market has seen rapid growth over the past few years increasing 38.5 percent from 2000 to 2005. Currently, this market ranks seventh world-wide with annual sales of approximately 3.5 Billion Dollars.
"We are very excited about the upcoming pre-launch of ForeverGreen Mexico. Our mission continues to be changing the world, one person at a time and at ForeverGreen we know that we can, and will, help and benefit tens of thousands of Mexican families," stated V.P. of Latin Business Development, Jorge Alvarado. "Pre-launch time is coming fast. Today, we already have many Hispanic families within the US territory who are enjoying and sharing ForeverGreen's message of Health, Kindness and Opportunity, and many of them have already talked to their friends, relatives and business-oriented people within the Mexican territory, which have literally spread the great news about ForeverGreen, FrequenSea and the Marine Phytoplankton even though the product is not yet in Mexico. As we speak, hundreds of Mexicans are preparing for the pre-launch of ForeverGreen Mexico. Positive energy is rising in Mexico and very soon our beloved Mexican people will join the beautiful ForeverGreen family." ForeverGreen will kickoff its pre-launch operations with an event this week in San Antonio, Texas to attract and educate distributors on this new opportunity. V.P. of Latin Business Development for ForeverGreen, Jorge Alvarado, will be joined by V.P. of Business Development, Rick Redford, and Hugo Rodier, M.D. to bolster awareness in the Latin-American community and preview the upcoming Mexican launch and the new opportunities this creates.
"ForeverGreen is expanding it international presence with addition of the Mexican market," commented ForeverGreen's CEO Ron Williams. "We view Mexico as a great opportunity for our FrequenSea and an exciting advancement for ForeverGreen. The Mexican people will be able to purchase and distribute FrequenSea this summer and start contributing to our sales growth during the third quarter." ForeverGreen Worldwide Corporation develops, manufactures and distributes an expansive line of all natural products to North America, Australia, Europe, and Asia. Offerings include FrequenSea(TM) a whole food beverage, Pulse(TM) a whole food snack or meal replacement, 24k Chocolate(R), and an entire catalog of meals, snacks, personal care items and essential oils.
As a trader, a very intelligent place to put your money, is where the money is flowing into. These are the kind of trades that you want to get into.
As the saying goes...follow the money!
To see the complete Movers & Shakers Blog go to: http://www.stockwire.com .
About Stockwire: Stockwire is a company that is pioneering a new way to research companies before you invest them. It's called a Stockumentary. A Stockumentary is a documentary on a publicly traded company. Imagine a Dateline NBC segment, but on a publicly traded company. We are the first company to ever bring this type of quality research to investors in this format.
The Stockumentary has video interviews with management, product demos, video tours of office or factory, research reports, sec filings and much more. All of this is delivered to investors in high quality video, either by mail or email.
Stockwire.com is owned by Stockwire Research Group Inc. (SRGI) and is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies.
As detailed below, this publication accepts compensation from some of the companies from which it features. To the degrees listed herein, this Newsletter should not be regarded as an independent publication. All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the Newsletter is neither an offer nor solicitation to buy or sell any securities mentioned.
While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.
We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at www.sec.gov and/or the National Association of Securities Dealers ("NASD") at www.nasd.com. The NASD has published information on how to invest carefully at its web site.
Readers can review all public filings by companies at the SEC's EDGAR page. www.sec.gov/edgar.shtml
Stockwire.com is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies. Stockwire.com is not a registered investment advisor or broker-dealer. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible.
From time to time SRGI sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies.
Moreover, as detailed below, this publication accepts compensation from third party consultants and/or companies which it features on Stockwire.com. Likewise, Stockwire.com is owned by Stockwire Research Group Inc. (SRGI). To the degrees enumerated herein, this newsletter and website should not be regarded as an independent publication.
All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company on Stockwire.com is neither an offer nor solicitation to buy or sell any securities mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.
The editor, members of the editor's family, and/or entities with which the editor is affiliated aside from Stockwire Research Group Inc. (SRGI) itself, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter.
THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN CONSENT OF THE EDITORS OF STOCKWIRE.COM.
We often accept restricted shares of company stock; by SEC regulations, restricted shares cannot be sold into the market for a period of at least one year from the time that the shares are issued. In such cases, we detail in the Disclaimer the specific term of any restrictions. We also receive compensation in the form of stock options, in which case we receive the right to buy shares of the stock of the company at issue, at a specified time and a specified price. In such circumstances, we specify on our Disclaimer the terms of the options received. On occasion, we also accept free-trading shares in a company that we cover. However, by policy we generally do not buy or sell any shares of a company's stock within three trading days after any such company's profile, commentary, or other company-specific information is disseminated on Stockwire.com Web site. In cases where we do trade within the three day window, our volume will never represent more than 5% of the daily volume, thereby minimizing any effect we could have on the potential price movement.
While our policies as detailed above are designed to minimize any impact upon our members of a conflict of interest between our company and our members, each member should be fully aware that such potential and actual conflicts of interest may well exist due to the compensation structure detailed herein. For this reason, and because the information contained on Stockwire.com is updated on a regular basis as circumstances change, each member is strongly encouraged to periodically review the Profile Compensation section at http://www.stockwire.com/disclaimer_profiles.htm
